Zydus Lifesciences saw a boost in its stock price on September 16 following the announcement of a key licensing and supply agreement with Viwit Pharmaceuticals, a US-based pharmaceutical firm. This partnership marks a significant move for Zydus as it strengthens its position in the US market for injectable products.
Zydus Lifesciences secures key licensing deal
Zydus Lifesciences shares were trading at ₹1,122.30 in the early hours of September 16, reflecting an increase of 0.34% from the previous trading day. This positive movement came after the announcement of an exclusive licensing and supply agreement with Viwit Pharmaceuticals. The partnership focuses on two Gadolinium-based Magnetic Resonance Imaging (MRI) contrast agents — gadobutrol injection (the generic version of GADAVISTTM) and gadoterate meglumine injection (the generic version of DOTAREM).
The agreement grants Zydus the exclusive rights to market, distribute, and sell these MRI contrast agents in the US. Viwit, on the other hand, will manage the Abbreviated New Drug Application (ANDA) submission, manufacturing, and supply of these products, contingent upon regulatory approvals.
Impact on Zydus’ injectable portfolio
This partnership brings Zydus Lifesciences its first set of contrast agents within its injectable portfolio aimed at the US market. Gadolinium-based MRI contrast agents enhance the quality of MRI scans, making them essential tools in diagnostic imaging.
For investors looking to buy shares online, this partnership with Viwit Pharmaceuticals could be a significant growth driver for Zydus Lifesciences. The US market offers vast potential, and securing exclusive rights for these products positions Zydus well for future success.
Broader market implications
Earlier in the month, Zydus also announced the successful completion of a Phase II(a) clinical study for its NLRP3 inhibitor, Usnoflast (ZYIL1), aimed at treating Amyotrophic Lateral Sclerosis (ALS). This development further showcases Zydus’ commitment to expanding its portfolio in critical medical areas.
For those considering share market investments, Zydus Lifesciences presents an interesting opportunity. With the exclusive US licensing deal and its ongoing clinical developments, the company is demonstrating its capacity to capture market share in competitive segments. If you're planning to buy shares online, Zydus Lifesciences’ stock might be worth considering.
Conclusion
The licensing and supply deal with Viwit Pharmaceuticals is a major milestone for Zydus Lifesciences. Not only does it enhance the company’s injectable portfolio, but it also opens up new avenues in the highly lucrative US market. For investors seeking to buy shares online, Zydus Lifesciences offers a compelling proposition with its expanding product range and ongoing clinical developments. As always, potential investors should closely monitor further announcements and regulatory approvals that could impact the company’s performance.
For android only